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SUMMARY
Kinase and phosphatase overexpression drives
tumorigenesis and drug resistance. We previously
developed amass-cytometry-based single-cell prote-
omicsapproach that enablesquantitativeassessment
of overexpression effects on cell signaling. Here, we
applied this approach in a human kinome- and phos-
phatome-wide study to assess how 649 individually
overexpressed proteins modulated cancer-related
signaling in HEK293T cells in an abundance-depen-
dent manner. Based on these data, we expanded the
functional classification of human kinases and
phosphatases and showed that the overexpression
effects include non-catalytic roles. We detected 208
previously unreported signaling relationships. The
signalingdynamics analysis indicated that the overex-
pression of ERK-specific phosphatases sustains
proliferative signaling. This suggests a phosphatase-
driven mechanism of cancer progression. Moreover,
our analysis revealed a drug-resistant mechanism
through which overexpression of tyrosine kinases,
including SRC, FES, YES1, and BLK, inducedMEK-in-
dependent ERK activation in melanoma A375 cells.
These proteins could predict drug sensitivity to
BRAF-MEK concurrent inhibition in cells carrying
BRAF mutations.
INTRODUCTION
Kinases and phosphatases control the reversible process of
phosphorylation. Signaling networks involving these enzymes
compute extracellular signals into transcriptional, functional,
and phenotypical responses. Deregulation of signaling networks
can lead to the initiation and progression ofmany types of human
disease, including cancer (Fleuren et al., 2016; Julien et al.,
2007). Signaling network structure has been studied by mapping
physical interactions of kinases and phosphatases in steady and
dynamic states using biochemical approaches and reporter
assays (Barrios-Rodiles et al., 2005; Breitkreutz et al., 2010;
Couzens et al., 2013; Horn et al., 2011). Using in vitro kinase
assays and motif-based predictions, the specificity and targets
of many kinases have been revealed (Linding et al., 2007; Mok
et al., 2010; Yu et al., 2009). Kinase and phosphatase perturba-
tions have been applied to systematically determine network
responses in yeast and human cells (Bodenmiller et al., 2010;
Ochoa et al., 2016; Sacco et al., 2012a).
Mutation-induced signaling network rewiring and modulation
of signaling dynamics have also been characterized for many
kinases (Creixell et al., 2015; Pawson and Warner, 2007),
providing a basis for the identification of targeted therapies in
cancer (Hennessy et al., 2005; Logue and Morrison, 2012). Inde-
pendently of mutations, kinase overexpression drives tumori-
genesis in multiple cancer types and is a critical factor in drug
resistance (Eralp et al., 2008; Santarius et al., 2010; Shaffer
et al., 2017). Recently, overexpression of phosphatases has
been shown to mediate cancer progression and has been linked
to the poor prognosis of patients (Julien et al., 2011; Liu et al.,
2016; De Vriendt et al., 2013). Overexpression-induced signaling
modulation remains largely uncharacterized because factors
such as genetic instability induce highly heterogeneous quanti-
ties of deregulated signaling proteins in cancer cells (Abbas
et al., 2013), making conventional cell population-based analysis
inapplicable. Only recently have technologies emerged that ac-
count for such heterogeneity and that can comprehensively
quantify signaling network behavior with single-cell resolution.
This resolution is required to characterize abundance-related
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cellular signaling states (measured as phosphorylation levels of
signaling proteins) and phenotypical alterations caused by a
given kinase or phosphatase of interest (Bendall et al., 2011;
Lun et al., 2017). Mass cytometry allows simultaneous quantifi-
cation of >40 proteins or protein modifications at single-cell res-
olution, enabling the profiling of complex cellular behaviors in
highly heterogeneous samples (Bendall et al., 2011; Bodenmiller
et al., 2012; Chevrier et al., 2017; Levine et al., 2015). We have
recently established and thoroughly validated an approach that
couples transient protein overexpression with mass-cytometry-
based, single-cell analysis and have revealed that protein over-
expression induces complex signaling network modulations in
an abundance-dependent manner (Lun et al., 2017).
Here, we applied this technique in a human kinome- and phos-
phatome-wide screen to determine kinase and phosphatase
abundance-dependent effects on 30 phosphorylation sites
known to be involved in the regulation of growth, proliferation,
survival, and stress signaling pathways. Over 10 million individ-
ual cells were analyzed, covering 649 overexpression conditions
with or without 10-min epidermal growth factor (EGF) stimula-
tion. Assessing the effects of kinase and phosphatase on the
signaling network, we expanded the functional classification
of the kinome and phosphatome. Our analysis identified 1,323
pairs of overexpression-dependent signaling relationships,
including 208 pairs that were previously unknown. By character-
izing signaling dynamics in a follow-up EGF stimulation time
course and a kinase-phosphatase combinatorial overexpression
assay, we found a pro-cancer signaling response in which the
overexpression of ERK-specific phosphatases sustained cell
proliferative signals. Further analysis of our dataset revealed a
drug-resistant mechanism through which the overexpression
of tyrosine kinases, including SRC, FES, YES1, and BLK,
induced MEK-independent ERK activation in melanoma A375
cells. The expression levels of these proteins could predict
drug sensitivity to BRAF-MEK concurrent inhibition in patients
with BRAF mutations and may be suggestive of alternative
treatments.
RESULTS
Abundance-Dependent Effects of Human Kinases and
Phosphatases on Cell Signaling
Protein abundance variance on the single-cell level is often
observed in tumors as heterogeneous genomic abnormalities
accumulate (Du and Elemento, 2015). Inter-tumoral heterogene-
ity presumably results in highly variable signaling responses to
stimuli or drug treatments. In addition, a high degree of intra-tu-
moral heterogeneity further challenges cancer therapeutic inter-
ventions (Patel et al., 2014; Roth et al., 2016). To understand the
signaling network modulation in cells that overexpress a defined
kinase or phosphatase at various levels, we applied our abun-
dance-dependent signaling network assessment system (Lun
et al., 2017) in a kinome- and phosphatome-wide screen.
We cloned open reading frames (ORFs) from the human kinase
library (Johannessen et al., 2010) and the human phosphatase li-
brary into a vector, enabling the expression of GFP-tagged
proteins (Couzens et al., 2013). The generated 541 kinase and
108 phosphatase expression clones (Table S1) were individually
transiently transfected into human embryonic kidney HEK293T
cells. Unstimulated cells and cells stimulated for 10 min with
EGF were harvested and processed with a 126-plex barcoding
strategy (adapted from Bodenmiller et al., 2012; Zunder et al.,
2015) for simultaneous antibody staining followed bymultiplexed
mass cytometry measurements (Figure 1A).
Transient transfection generates a single-cell gradient of the
GFP-tagged protein of interest (POI) expression levels with up
to 1,000-fold enhancement relative to the endogenous POI
expression range (Lun et al., 2017). The abundance variation of
each overexpressed kinase or phosphatase was quantified on
the single-cell level by mass cytometry with detection by a
metal-conjugated anti-GFP antibody. Simultaneously, we quanti-
fied 30 phosphorylation states of proteins involved in key cancer-
related signaling pathways, including the AKT, protein kinase C
(PKC), signal transducer and activator of transcription (STAT),
mitogen-activated protein kinase (MAPK)/ERK, and stress path-
ways, and 5 non-signalingmarkers indicative of cell physiological
states (Table S2). Over 10million individual cells were analyzed in
the 659 overexpression conditions with or without 10-min EGF
stimulation, averaging 7,000 measured cells per sample. That
theGFP-tagging system rarely influenced protein overexpression
effects has been previously reported (Lun et al., 2017).
The dependence of phosphorylation levels on the abundance
of GFP-tagged POI was quantified by the binned pseudo-R2
(BP-R2) method, a density-independent measure of signaling
relationship strength (Figures S1A and S1B) (Lun et al., 2017).
We confirmed that signaling relationships assessed with our
approach were reproducible in five different cell lines from multi-
ple tissues of origin (Figure S1C). We analyzed 108 control sam-
ples (FLAG-GFP overexpression or untransfected cells) and used
the highest BP-R2 score (0.13) of all of the controls as the cutoff to
consider a signaling relationship as ‘‘strong.’’ In total, our human
kinomeandphosphatomeanalysis detected 1,323 pairs of strong
relationshipsbetweenPOIsandphosphorylationsites (Figure 1B).
Among the 649 kinases and phosphatases, 327 (50.4%) had
at least 1 strong signaling relationship to the cancer-related
signaling networkwhen overexpressed.Of these, 245 had narrow
influences with the modulation of 1–5 signaling nodes, and
26 overexpressed proteins had broad effects on the network
with >10measuredphosphorylation sites influenced (FigureS1D).
We identified 49 proteins that affected all of the measured
signaling pathways, including 11 receptor proteins (e.g., MET,
fibroblast growth factor receptor 1 [FGFR1], and platelet-derived
growth factor receptor A [PDGFRA]) and many MAPK cascade
activators (e.g., MAP4K1, MAP4K2, and MAP4K5) (Figure 1C).
To characterize how POI abundance modulates intracellular
signaling, we performed shape-based clustering (see STAR
Methods) on all of the detected strong signaling relationships.
We classified these relationship shapes into 10 shape clusters
(Figure 1D). Shapes 1–5 involve overexpression-induced signal
upregulation, with sensitivity to abundance changes increasing
from shape 1 to shape 5. Shape 6 is non-monotonic signaling re-
lationships, as phosphorylation levels initially increase and then
decrease as a function of POI abundance. Shapes 7–10 reflect
overexpression-induced signaling downregulation, with sensi-
tivity to POI abundance changes increasing from shape 7 to
shape 10 (Figure 1D). Overexpression of a particular POI can
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affect different phosphorylation sites with dissimilar shapes of
relationship (Table S3). We also found that 250 pairs of signaling
relationships had different shapes before and after EGF stimula-
tion, indicating that POI levels determine the strength of the
signaling response to EGF stimulation.
Altered responses to EGF stimulation are the potential results
of network topology modulations (Koseska and Bastiaens, 2017;
Santos et al., 2007) that are induced by POI abundance changes.
To verify this, we focused on two pairs of EGF-induced shape-
switching relationships, KSR2 to p-MAPKAPK2 (MAPKAPK2
signaling is essential for tumor cell survival; Morandell et al.,
2013) and TEC to p-ERK1/2 (a pair of non-monotonic rela-
tionship). We performed additional perturbation experiments us-
ing MEK inhibitor CI1040 and characterized signaling network
B C
A
D
Figure 1. Kinome- and Phosphatome-wide Screen for Effects of Protein Abundance on Signaling States and Dynamics
(A) The experimental workflow: ORFs of 541 human kinases and 108 human phosphatases were cloned into a vector encoding GFP-tagged fusion proteins upon
transient transfection into HEK293T cells. Cells with or without 10-min EGF stimulation were harvested, barcoded, and stained with antibody mix before mass-
cytometry-based single-cell analysis.
(B) Plot of counts versus BP-R2 values for control and experimental samples. Cutoff value was determined by analysis of the BP-R2 values in all of the control
samples. Square-root transformation was applied on the y axis.
(C) Venn diagram showing the quantification of POIs with abundance-dependent influences on the AKT pathway (p-PDK1, p-GSK3b, b-catenin, p-mTOR,
p-p70S6K, p-4EBP1, and p-S6), MAPK-ERK pathways (p-RAF, p-MEK1/2, p-ERK1/2, p-p90RSK, p-CREB, and p-SMAD2/3), stress response pathways
(p-MKK3/6, p-MKK4/7, p-p38, p-JNK, p-MAPKAPK2, p-AMPKa, and p-p53), and PKC and STAT pathways (grouped for illustration purposes; p-SRC, p-FAK,
p-BTK, p-PLCg2, p-MARCKS, p-NFkB, p-STAT1, p-STAT3, and p-STAT5).
(D) Shape-based clustering on all strong signaling.
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variations over a large dynamic range of POI concentrations.
We found that at the medium expression levels of KSR2,
MAPKAPK2 phosphorylation was MAPK-ERK cascade-depen-
dent and that it could be highly induced by EGF stimulation;
high KRS2 expression levels contributed to MAPK-ERK-inde-
pendent MAPKAPK2 signaling that had a weak response to
EGF stimulation and was insensitive to MEK inhibition (Figures
S1E–S1G). Increased TEC abundance led to non-monotonic
ERK1/2 phosphorylation that was partially diminished by MEK
inhibition (Figure S1H), indicating the presence of both MEK-
dependent and MEK-independent pathways for the TEC over-
expression-induced ERK activation. The MEK-dependent
signaling was reduced at high TEC expression levels, potentially
due to a negative regulatory mechanism that is only activated in
the presence of high concentrations of TEC (Figures S1H–S1J).
Here, by characterizing signaling network variations over a large
dynamic range of POI concentration, our analysis revealed com-
plex modulations of signaling network topology in a protein
abundance-dependent manner.
Functional Classification of Kinases and Phosphatases
Based on Signaling Network Modulations
To understand the regulatory and functional similarity of overex-
pressed POIs, we indicated the sign for signaling relationships
(according to their directionality) to the BP-R2 (Table S4; STAR
Methods). Then, we applied the dimensional reduction algorithm
t-distributed stochastic neighbor embedding (t-SNE) (van der
Maaten and Hinton, 2008) to the matrix of all 60 measured
signaling parameters (as signed-BP-R2 scores) over the 327
signaling network-influential kinases and phosphatases (Fig-
ure 2A). As expected, homologous groups of kinases and phos-
phatases showed nearly identical influences on signaling and
overlapped with each other on the t-SNE plot (Figure 2A, green
boxes). This demonstrates that our method sensitively, specif-
ically, and reproducibly detected abundance-dependent
signaling behaviors. All eight overexpressed SRC family mem-
bers—SRC, YES1, BLK, LCK, LYN, HCK, FGR, and FRK—co-
localized in the t-SNE analysis (Figure 2A, purple box), indicating
that these kinases have similar abundance-dependent signaling
effects, despite the previously revealed differential patterns of
expression (Parsons and Parsons, 2004). Members of protein
tyrosine phosphatase (PTPN1, PTPN2, and PTPN5) and dual-
specificity phosphatase (DUSP3, DUSP4, DUSP6, DUSP7,
DUSP10, and DUSP16) familieswere grouped together, suggest-
ing similarities in regulating the measured cancer signaling
network (Figure 2A, orange box).
We then applied hierarchical clustering based on signed-BP-
R2 scores of all of the measured phosphorylation sites (Figures
S2A and S2B) to further analyze functional similarities among
all of the kinases and phosphatases. This led to the identification
of 10 major signaling response clusters (color coded on the
t-SNE plot in Figure 2A). Correspondence analysis was per-
formed between these identified clusters and classes of kinases
and phosphatases previously established based on catalytic
domain sequences (Johannessen et al., 2010; Sacco et al.,
2012b) (Figure S2C). In certain cases, proteins with partial
sequence identity had similar influences on signaling. For
example, all of the kinases in cluster 1 are receptor or non-recep-
tor tyrosine kinases (Figure S2C). These kinases are early re-
sponders to stimuli, as shown in the literature-based graph of
canonical EGF receptor (EGFR) networks (Figure 2B). Clusters
5, 9, and 10 include non-receptor serine or threonine kinases
and kinases classified in the group of ‘‘other’’ (i.e., kinases that
do not fit into any of the major groups) (Figure S2C). Despite
conserved catalytic domain sequences, kinases in clusters 5,
9, and 10 induced different cellular responses (Figure 2B). Clus-
ter 7 proteins had negative relationships with the mediators of
the MAPK-ERK pathway when cells were treated with EGF (Fig-
ure 2B). Cluster 7 mostly consists of protein tyrosine phospha-
tases, but also includes a few proteins from the classes of
non-receptor serine or threonine kinase and lipid kinases (Fig-
ure S2C). Comparing our identified clusters to the phylogenetic
tree of the human kinome (Eid et al., 2017; Manning et al.,
2002), we observed the enrichment of cluster 1 in the tyrosine
kinase group (Figure S2D, orange arrow). In addition, PKC family
members are enriched in cluster 5 (Figure S2C, brown arrow),
and MAP3Ks are enriched in cluster 9 (Figure S2D, blue arrow).
In summary, the human kinome- and phosphatome-wide over-
expression analysis identified 10 clusters of kinases and phos-
phatases, with distinct signaling patterns found for each cluster.
These clusters partially matched the sequence-based classifica-
tion and expanded the functional classification of the human ki-
nases and phosphatases based on their abundance-dependent
modulations to the cancer signaling network.
Functional Enrichment Analysis of Kinase and
Phosphatase Clusters
Our analysis indicated that signaling proteins with different cata-
lytic domain sequences may affect signaling networks similarly
when overexpressed. To understand the functional relationship
between proteins with similar overexpression effects, we per-
formed a functional enrichment analysis using the STRING
database (Szklarczyk et al., 2017) on the 10 identified clusters
(Figures 2A and 3A). We found that 7 of the 10 clusters had sig-
nificant functional enrichment (p < 0.01; statistical details in
STARMethods). Physical and functional interaction enrichments
are shown as protein-protein association networks for cluster 7
in Figure 3B and for all other clusters in Figure S3A.
Cluster 7 is enriched for protein tyrosine phosphatases that
negatively regulate MAPK pathways. Several MAPK regulating
kinases are present in this cluster, including KSR1 and ARAF,
which have overexpression effects similar to those of the phos-
phatases (Figure 3B). KSR1 and ARAF are core components of
the KSR-RAF dimeric protein complex that transduces signal
Figure 2. Kinase and Phosphatase Classification Based on Abundance-Dependent Effects on Cancer Signaling Network
(A) t-SNE analysis of overexpressed kinases and phosphatases performed on signed-BP-R2 of all measured phosphorylation sites with and without EGF
stimulation, color coded by hierarchical clusters.
(B) The mean signed-BP-R2 values of all measured phosphorylation sites in each cluster of kinases or phosphatases shown in literature-guided canonical
signaling network visualizations.
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in the MAPK-ERK cascade (Lavoie and Therrien, 2015). Overex-
pressing one subunit of this protein complex may result in
competitive inhibition, diminishing the downstream signal activ-
ities in a manner similar to that of phosphatase overexpression.
These analyses demonstrated that proteins with different cata-
lytic functions can mediate highly related signaling responses
when overexpressed and that kinase overexpression does not
affect signaling networks in the same manner as direct kinase
activation.
To assess the relationship between overexpression effects and
protein catalytic activities, we chose to overexpress five kinase-
dead mutants: AKT3K177M, AXLK567R, MAPK3K71R, PRKCEK437W,
and MAP2K1K97M. Unlike wild-type kinases, the overexpression
of kinase-dead mutants AXLK567R and PRKCEK437W had almost
no network effect (Figure S3B), indicating that the detected abun-
dance-dependent network modulations of these kinases are
related to their catalytic functions. In contrast, the main network
effects of AKT3, MAPK3, and MAP2K1 were also observed
when the kinase-deadmutantswere overexpressed (FigureS3B).
This suggests that overexpression-induced signaling network
modulations for these kinases are non-catalytic. In addition, 26
kinases in our screenwere previously predicted to be catalytically
inactive (Manning et al., 2002). We found that 6 of these 26 pro-
teins influenced the measured network, with a total of 17 pairs
of strong signaling relationships detected (Table S5), also
demonstrating that our analysis captured non-catalytic network
A
B
Figure 3. Functional Enrichment Analysis of Kinases and/or Phosphatases in Each Cluster
(A) An unrooted tree shows the hierarchical clustering of the kinases and phosphatases based on their signed-BP-R2 scores. Terms of enriched functions
(p < 0.05) from each cluster are annotated, with circle color indicating the p value and circle size showing the coverage of cluster components. The percentage of
associated proteins is indicated by the size of the adjacent circle.
(B) Functional association analysis performed with the STRING database (Szklarczyk et al., 2017) for cluster 7. Confident edges are shown in the network.
Functional enrichments are shown as color-coded pies, with the pie radius indicating the p value.
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modulations determined by kinase abundance. In summary,
these data show that protein overexpression effects can be cat-
alytic or non-catalytic and suggest that activity-based modeling
of signaling network deregulation for drug target discovery alone
is likely insufficient.
Signaling Relationships Detected in Kinome- and
Phosphatome-wide Analysis
The functions of many kinases and phosphatases analyzed in
our screen are unknown or only poorly characterized. We
hypothesized that our global analysis could lead to the identifica-
tion of signaling relationships. To assess this, we performed a
systematic comparison between all identified overexpression-
induced signaling relationships and records in OmniPath, an
integrated database of literature-curated signaling interaction
information (T€urei et al., 2016). We first mapped all pairs of rela-
tionships to the OmniPath signaling network and then computed
the signed, directed paths for each pair of relationship (Krumsiek
et al., 2011; Perfetto et al., 2016). The distance between an over-
expressed protein and ameasured phosphorylation site is repre-
sented by the length of the path (Figure 4A). For example, a
distance of 0 indicates the relationship between the overex-
pressed POI and its own phosphorylation levels. Of 14 pairs of
signaling relationships with a known distance of 0, 12 had strong
BP-R2 values with and without 10-min EGF stimulation (Fig-
ure 4A), revealing that the phosphorylation level of a particular
kinase is often determined by its own abundance, even in the
absence of additional perturbation.
We detected 208 (16%) strong relationships (BP-R2 > 0.13)
with infinite distance (Figure 4A; Table S6), which is indicative
of connections not described previously. In total, 93 overex-
pressed POIs contributed to these signaling relationships, which
were enriched (in absolute count) in clusters 2, 3, and 4 and to a
lesser extent in cluster 6 (Figure 4B). We did not detect any rela-
tionships with infinite distance in clusters 9 or 10 (Figure 4B);
POIs from these clusters participate inMAPK signal transduction
(Figure 3A), which is well characterized. We also assessed the
distribution of infinite paths for each kinase and phosphatase
class and did not detect any enrichment (Figure S4A). There
were 132 pairs of strong relationships between proteins with
length of signed directed path >3 in OmniPath, suggesting
potentially undiscovered direct or short-range connections
(Figure 4A).
Many potential signaling relationships were related to disease
and to poorly characterized kinases (Figures 4C, 4D, and S4B).
For instance, high levels of RIOK2 (highlighted in Figure 4C)
have been recently shown to correlate with the poor prognosis
of patients with non-small-cell lung cancer, but the underlying
signaling mechanisms are unclear (Liu et al., 2016). We discov-
ered that RIOK2 overexpression affected several phosphorylation
sites, most strongly Thr172 on adenosine 50 monophosphate-
activated protein kinase a (AMPKa), Ser257/Thr261 on MKK4/7,
and Thr180/Tyr182 on p38 (Figure 4C), indicating the activation
of the AMPK-p38 axis upon RIOK2 overexpression. The AMPK-
p38 axis regulates cellular energy metabolism, contributing to
cancer cell survival in nutrient-deficient conditions (Chaube
et al., 2015; Zadra et al., 2015). In cancer proteome data from
the Clinical Proteomic Tumor Analysis Consortium (Koboldt
et al., 2012), we found that expression levels of RIOK2were highly
correlated with levels of AMPK subunits b and g and the AMPK
activator LKB1 (STK11), confirming RIOK2 as a co-regulatory
kinase in the AMPK signaling pathway (Figures S4C and S4D).
A C
B
D
Figure 4. Prediction of Potential Signaling Connections by Comparison with Literature Evidence in the Signaling Interaction Database
OmniPath
(A) Abundance-dependent relationship strength for each pair of overexpressed POIs and measured phosphorylation site, as quantified with signed-BP-R2,
plotted on the length of shortest signed, directed path between the two extracted from the OmniPath database (T€urei et al., 2016).
(B) Occurrences of strong signaling relationships (BP-R2 > 0.13), with path length from 0 to 5 or infinite path length (OmniPath) in each individual hierarchical
cluster.
(C and D) For clusters 8 (C) and 5 (D), respectively, the shortest signed directed path length for each determined strong signaling relationship is shown in Circos
plots (Krzywinski et al., 2009).
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Figure 5. Effects of EGF Stimulation on 39 Kinases and Phosphatases
(A) Heatmap of signed-BP-R2 scores for measured signaling relationships over a 1-h EGF stimulation time course. Six identified groups of kinases and phos-
phatases are labeled in color codes.
(B) For one representative POI from each group, signaling relationships to all measured phosphorylation sites, as quantified by signed-BP-R2, are shown in the
literature-guided canonical signaling network map.
(C–G) Violin plots show cell distribution in each of 10 bins based on GFP-tagged POI expression levels (see STAR Methods) for EGFR-GFP to p-ERK1/2 (C),
DUSP4-GFP to p-ERK1/2 (D), PTPN2-GFP to p-ERK1/2 (E), DUSP4-GFP to p-MEK1/2 (F), and PTPN2-GFP to p-MEK1/2 (G) over the 1-h EGF stimulation time
(legend continued on next page)
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To further illustrate the clinical relevance of overexpression-
induced AMPK activation, we coupled our data of kinase and
phosphatase overexpression effects with the proteome data of
breast cancer and ovarian cancer patients and their prognosis in-
formation (Mertins et al., 2016; Zhang et al., 2016) (Figures S4E
and S4F). We found three kinases (CSNK1A1, NEK7, and TLK1)
and a phosphatase (CDC25C) inducing AMPK activation when
overexpressed and affecting patient outcomes; patients overex-
pressing any of these kinases had significantly worse prognoses
in comparison to the patients underexpressing the same kinase
(Figures S4G and S4H). Our data suggest that kinase overexpres-
sion-induced AMPK activation is related to the prognosis in can-
cer patients and that AMPK is a potential therapeutic target for
patients overexpressing proteins, such as RIOK2, CSNK1A1,
CDC25C, NEK7, and TLK1.
Overexpression of a poorly characterized kinase, MGC42105
(NIM1K), in cluster 5 (highlighted in Figure 4D) modulated the
phosphorylation of Ser241 on PDK1, Thr389 on p70S6K, and
Ser235/Ser236 on S6, suggesting a role in growth signaling.
MGC42105 also induced abundance-dependent activation of
stress pathways, as strong relationships to p-p53 (Ser15) and
p-AMPKa (Thr172) were observed (Figure 4D). In summary,
mapping our identified signaling relationships to the OmniPath
database enabled the assignment of signaling functions to a
number of kinases and phosphatases and shed light on potential
signaling mechanisms associated with the poor prognosis of
cancer patients.
In-Depth Analysis of Signaling Dynamics Reveals
Overexpression-Dependent MAPK-ERK Activity
An understanding of signaling dynamics is essential for identi-
fying diseased signaling circuits within a network and in the pre-
diction of drug efficiency (Du and Elemento, 2015; Hughey et al.,
2010). We have previously shown that altering the expression
levels of central signaling proteins in the EGFR signaling network
results in complex changes in network dynamics (Lun et al.,
2017). Given the key role of signaling dynamics on cell prolifera-
tion, growth, and differentiation (Koseska and Bastiaens, 2017),
we systematically evaluated kinases and phosphatases from the
10 identified clusters for overexpression-induced signaling dy-
namic modulations. We calculated the differences in signed-
BP-R2 scores between the EGF-stimulated and -unstimulated
conditions to identify cases in which overexpression modulated
signaling dynamics (i.e., altered the strength or the shape of
abundance-dependent signaling relationships between the un-
stimulated and the 10-min EGF-stimulated conditions). We
found that POIs in clusters 1, 6, 7, 9, and 10 strongly modulated
signaling network dynamics when overexpressed (Figure S5A).
We then analyzed the overexpression effects of the top 39
dynamic-modulating POIs over a 1-h EGF stimulation time
course. The dynamic responses of all of the measured phos-
phorylation sites are shown in Figures 5A and 5B. Example
signaling relationship shapes at each time point during the time
course and the POI abundance-dependent signaling trajectories
over the time course are shown in Figures 5C–5G. Features of
the signaling amplitudes (see STAR Methods) are shown in Fig-
ures S5F–S5H.
Hierarchical clustering of the overexpression-induced EGFR
signaling dynamics classified the 39 selected proteins into
6 groups (Figures 5A and S5B). Signaling network responses
for one representative kinase or phosphatase from each of the
six identified groups are illustrated in Figure 5B. We showed
that the network responses to EGF stimulation were highly spe-
cific to cell lines (Figure S5C). In HEK293T cells, EGF stimulation
strongly activated the MAPK-ERK signaling pathway and had
weak effects on the AKT, PKC, STAT, or stress response path-
ways (Figure S5C). Similarly, we observed that EGF stimulation
primarily influenced the POI abundance-dependent dynamics
of the MAPK-ERK signaling cascade rather than the AKT, PKC,
and STAT pathways (Figure 5A). As the MAPK-ERK proliferative
pathway is known to be involved in tumor progression and drug
response, we focused our subsequent analyses on this pathway
in HEK293T cells.
Phosphorylation of Thr202/Tyr204 on ERK1/2 was elevated in
cells with high levels of GFP-tagged EGFR in the absence of
EGF stimulation (Figures 5B and 5C). These cells did not
respond to EGF stimulation, indicating ligand-independent
ERK activation (Figures 5C and S5G). Since the ligand-indepen-
dent ERK activation is known as a cancer-driving mechanism
(Guo et al., 2015), we next sought to systematically identify
signaling proteins causing similar abundance-dependent ligand
insensitivity. Applying shape-based clustering, we classified
p-ERK1/2 signaling trajectories during the 1-h EGF stimulation
time course, over the range of expression levels of each
analyzed POI. We found that overexpression of kinases
TYRO3, TEC, MST1R, MOS, MET, MAP3K8, FGF1R, and
ABL1 also led to prolonged ERK1/2 activation (Figures S6A–
S6D). These proteins have been previously shown to mediate
oncogenic signaling (Duan et al., 2016; Johannessen et al.,
2010; Paul and Mukhopadhyay, 2004; Salgia, 2017).
In the absence of EGF stimulation, overexpression of phos-
phatases DUSP4 and PTPN2 did not affect the levels of phos-
phorylation in the MAPK-ERK pathway (Ser221 on MEK1/2,
Thr202/Tyr204 on ERK1/2, or Ser380 on p90RSK) (Figures 5B,
5D–5G, S5D, and S5E). This suggests either a mechanism that
compensates for phosphatase overexpression to maintain basal
MAPK-ERK signaling or that the overexpressed phosphatases
are inactive without EGF stimulation. Upon EGF stimulation,
signaling dynamics on phosphorylation sites of the MAPK-ERK
pathway were modulated by DUSP4 and PTPN2 in an abun-
dance-dependent manner as negative signaling relationships to
p-ERK1/2 and p-p90RSK were detected (Figures 5B, 5D, 5E,
S5D, and S5E). DUSP4 or PTPN2 overexpression also resulted
in reduced p-ERK1/2 and p-p90RSK amplitudes (Figure S5H).
course. Medians of all 10 bins are connected to indicate the shape of signaling relationships (black lines), with the relationship strength quantified by signed-BP-
R2, as shown on top of each individual plot. In the plot on the far right, medians of each bin are connected over the time course to demonstrate the POI
abundance-dependent signaling trajectories.
(H) Schematic illustration of how two sets of phosphatases induce different abundance-dependent influences on the signaling dynamics of the MAPK-ERK
cascade.
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Different p-MEK1/2 dynamics were observed in cells overex-
pressing these two phosphatases. In response to the EGF stim-
ulation, cells with DUSP4 overexpression had more sustained
MEK1/2 activation (Figure 5F) compared to cells with PTPN2
overexpression (Figure 5G). DUSP4 has been shown to specif-
ically target ERK1 and ERK2 (Guan and Butch, 1995). Our data
indicate that by diminishing ERK1/2 phosphorylation, the overex-
pressed DUSP4 attenuates the negative feedback from ERK1/2
to MEK1/2, resulting in constant activation of MEK1/2. Sub-
strates of PTPN2 are primarily membrane kinases, including
EGFR (Mattila et al., 2005). As expected, overexpression of
PTPN2 downregulated the activation of all measured signaling
proteins known to be downstream of EGFR, including MEK1/2
and ERK1/2 (Figure 5H).
To systematically classify all overexpressed phosphatases
based on the signaling dynamics, we performed shape-based
clustering on p-MEK1/2 trajectories during the 1-h time course
after EGF addition, over the expression levels of each POI (Fig-
ures S6E–S6H). Abundance-dependent prolonged MEK1/2
phosphorylation was observed with other phosphatases in
group E, including DUSP6, DUSP7, DUSP10, DUSP16, and
PTPN7, indicating that Thr202 and Tyr204 on ERK1/2 are sub-
strates of these enzymes (Figure 5H). DUSP10 and DUSP16
have been previously reported to be JNK- and p38-specific
phosphatases (Finch et al., 2012; Masuda et al., 2003). Here,
we show that DUSP10 and DUSP16, expressed at high abun-
dance, also dephosphorylate p-ERK1/2 and attenuate the
MAPK-ERK signaling, thereby likely decreasing the negative
feedback from ERK1/2 to MEK1/2 and causing sustained
MEK1/2 activation (Figures 5A and 5H).
Pairwise Overexpression Analysis Reveals that
Phosphatases Sustain Kinase-Induced MAPK-ERK
Signaling
Phosphatase overexpression is oncogenic in different tumor
types, but the signaling mechanisms remain unclear (Julien
et al., 2007, 2011). Recent work indicates that overexpressed
phosphatases increase the malignancy of cancers that have a
hyperactivated MAPK-ERK pathway (Julien et al., 2007; Low
and Zhang, 2016; De Vriendt et al., 2013). Our data suggest a
mechanism through which overexpression of ERK-specific
phosphatases sustains MEK phosphorylation levels (Figures 5F
and 5H). To assess whether an additional, secondary signaling
input that increases MAPK pathway activity could lead to
phosphatase-driven oncogenic-like signaling, we developed a
combinatorial transfection assay in which overexpression of a
kinase and a phosphatase were detected via an FLAG-tag and
a GFP-tag, respectively, providing a two-dimensional analysis
of abundance-dependent signaling modulations on the single-
cell level (Figure 6A). Using this approach, we analyzed the
MAP2K2, MAPK1, and RPS6KA1 (also known as MEK2, ERK2,
and p90RSK1) kinases and the DUSP4, DUSP7, and PTPN2
phosphatases in 9 combinations of double overexpression
over a 1-h EGF stimulation time course (Figure 6B).
When overexpressed individually, we observed that DUSP4
overexpression sustained the phosphorylation of Ser221 on
MEK1/2 over the 1-h EGF stimulation time course, likely due to
the weakened ERK-to-MEK negative feedback (Figures 6C and
6D). MAP2K2-FLAG overexpression led to an increased MEK1/2
phosphorylation (Figure 6C). MAP2K2-FLAG and DUSP4-GFP
co-overexpression further increased the hyperactivated states
of MEK1/2 over the 1-h EGF stimulation time course compared
to the activation inducedbyMAP2K2-FLAGoverexpression alone
(Figures 6C–6E). Moreover, in cells with simultaneously overex-
pressed MAP2K2-FLAG and DUSP4-GFP, the downstream
ERK1/2 phosphorylation on Thr202 and Tyr204 were inhibited
(Figures 6C–6E). Previously, highly activated MEK1/2 was
observed to lead to ERK-independent oncogenic-like signaling
(Burgermeister and Seger, 2008; Takahashi-Yanaga et al., 2004).
The overexpression of FLAG-tagged MAPK1 (ERK2) drasti-
cally augmented ERK1/2 phosphorylation during EGF stimula-
tion (Figure 6F), increased p-ERK1/2 amplitudes, and delayed
p-ERK1/2 peak times (Figure 6G) in agreement with a previous
study of the effect of MAPK1 overexpression (Lun et al.,
2017). The simultaneous overexpression of MAPK1-FLAG and
DUSP7-GFP decreased p-ERK1/2 levels at all time points and
reduced the signaling amplitudes. Furthermore, DUSP7 overex-
pression delayed p-ERK1/2 peak times upon EGF stimulation: in
cells with the highest MAPK1 abundance and mid-level overex-
pression of DUSP7, ERK1/2 phosphorylation peaked at 30 min
after the addition of EGF (Figures 6F and 6G, purple arrows),
whereas in untransfected cells, p-ERK1/2 peaked at the 5-min
time point (Figures 6F and 6G). As expected, DUSP7 overex-
pression also resulted in constant MEK1/2 phosphorylation
(Figures 6F and 6G, green arrows). Compared to cells overex-
pressing onlyMAPK1 (ERK2), which induced strong but transient
ERK activation, the additional low-to-mid levels of DUSP7
decreased the ERK1/2 phosphorylation amplitude and partially
limited the negative feedback signal from ERK to MEK, inducing
a sustained MEK activation and a prolonged ERK signal. Thus,
our analysis indicates that overexpression of certain phospha-
tases, such as DUSP4 and DUSP7, led to sustained activation
Figure 6. Effect of Pairwise Overexpression of a Kinase and a Phosphatase on Signaling
(A) Workflow of the pairwise overexpression. Two plasmids encoding an FLAG-tagged kinase and a GFP-tagged phosphatase were transfected into HEK293T
cells successively. Cells were binned into 25 groups according to their FLAG and GFP abundances. Themedian level of eachmeasured phosphorylation site was
computed for each bin.
(B), Kinases MAP2K2, MAPK1, and RPS6KA1 and phosphatases DUSP4, DUSP7, and PTPN2 were selected for the pairwise overexpression, generating nine
overexpression combinations in total.
(C) In cells with overexpression of MAP2K2 and DUSP4, median phosphorylation levels of p-MEK1/2 and p-ERK1/2 are plotted for all of the bins over the 1-h EGF
stimulation time course.
(D) Signaling trajectories of p-MEK1/2 and p-ERK1/2 plotted as the medians of each individual bin over the 1-h EGF stimulation time course.
(E) Schematic illustrating the modulation of RAF-MEK-ERK cascade signaling states and dynamics upon pairwise overexpression.
(F and G) Analysis of p-ERK1/2 and p-MEK1/2 phosphorylation levels (F) and signaling trajectories (G) on MAPK1-FLAG and DUSP7-GFP abundances.
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Figure 7. Kinase Overexpression Induces Resistance to BRAF-MEK Concurrent Inhibition in Melanoma Cells by MEK-Independent ERK
Reactivation
(A) Selected kinases were transfected into A375 cells and cultured in the inhibitor- or DMSO-containing media, and signaling states and cell viability were
assessed.
(B) Single-cell data from each sample were divided into four bins, depending on the expression level of the GFP-tagged kinase. Signed-BP-R2 analysis was
performed to quantify signaling relationships with and without vemurafenib.
(C) The proportion of cells in bin 4, cells with the highest levels of POI, for each individual overexpressed kinase in vemurafenib-treated cells and DMSO-treated
cells. (*p < 0.05; **p < 0.01; ***p < 0.001, n = 3).
(legend continued on next page)
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of ERK due to the reduced negative feedback strength. This
mechanism may underlie the pro-cancer effects of phosphatase
overexpression.
Analysis of the Abundance-Dependent Signaling
Relationship Characterizes Drug-Resistance
Mechanisms
As protein overexpression has been correlated with drug resis-
tance of cancer cells (Johannessen et al., 2010, 2013; Shaffer
et al., 2017), we next sought to determine whether our kinome-
and phosphatome-wide signaling network profiles could identify
kinases or phosphatases that, when overexpressed, induce drug
resistance and could characterize underlying signaling mecha-
nisms. In melanoma cells carrying the BRAFV600E mutation, the
overexpression of certain kinases is associated with de novo
or acquired resistance to MAPK-ERK inhibition; Johannessen
et al. (2010, 2013) have identified resistance-driving candidate
genes in viability assays using melanoma A375 cells. Seventeen
of these candidates were analyzed in our screen, and the
overexpression of 14 caused abundance-dependent signaling
modulations to p-ERK1/2 (Thr202/Tyr204) in unstimulated cells
(Figure S7A). The 10-min EGF stimulation reduced relationship
strengths for each of these kinases (Figure S7B), indicating
that these overexpression-related ERK activations were ligand-
binding independent (described above with Figure 5C), which
has been previously suggested to be a drug-resistance mecha-
nism (Guo et al., 2015).
In our kinome- and phosphatome-wide study, we detected 54
POIs that activated ERK in the absence of EGF (Table S7). To
determine whether the overexpression of these proteins is
predictive of drug resistance in cells with BRAF mutations, we
transfected A375 cells, a melanoma cell line with the BRAFV600E
mutation, using vectors encoding proteins with the strongest
abundance-dependent signaling relationship to p-ERK1/2;
ABL1, BLK, FES, MAP3K2, MAP3K8, MOS, NTRK2, SRC, and
YES1. MEK1DD, a constitutively active kinase, was used as a
positive control (Johannessen et al., 2010). Cells were subse-
quently treated for 48 h with the BRAFV600E inhibitor vemurafenib
or with DMSO (Figure 7A). The strong signaling relationships
between these POIs and p-ERK1/2 were observed only in cells
treated with vemurafenib, not in control cells treated with
DMSO (Figures 7B, S7C, and S7D). This suggests that (1) the
constitutive BRAF activation caused by the BRAFV600E mutation
leads to strong MAPK-ERK activation that overrides the overex-
pression effects, and (2) POI abundance-dependent ERK
signaling is independent of RAF activity. To determine whether
overexpression of these candidate POIs reduced sensitivity to
the BRAFV600E inhibitor vemurafenib, we assigned each single
cell into one of four bins based on the abundance of GFP-tagged
POI and calculated the percentage of cells in each bin relative to
the total cell count (Figure 7B). As expected, the positive control
cells that expressed MEK1DD-GFP had significant cell enrich-
ment in the fourth bin (i.e., the bin with the highest expression
level of the GFP-tagged POI), with vemurafenib treatment
compared to the DMSO-treated control (Figure 7C). This indi-
cates that MEK1DD overexpression contributes to cell survival.
Similarly, all nine examined kinases showed an enrichment of
cell abundance in the fourth bin; in six cases, this enrichment
was statistically significant (Figure 7C). These results reveal
that in melanoma A375 cells, the overexpression of kinases
capable of ligand-independent ERK activation reduces cellular
dependency on signaling inputs from BRAFV600E.
Three of the tested kinases, MAP3K8, MOS, and SRC, were
previously suggested to mediate MAPK-ERK inhibition resis-
tance in A375 cells (Johannessen et al., 2013). In analyzing the
cell viability data in the same study, we noted that MAP3K8
and MOS only induced resistance to RAF inhibition, whereas
SRC overexpression caused resistance to both RAF and MEK
individual inhibitions and the concurrent RAF-MEK inhibition
(Figure S7E) (Johannessen et al., 2013). We hypothesize that
the difference in drug responses are due to theMEKdependency
of the POI overexpression-induced ERK activation (i.e., an over-
expressed POI directly activating ERK will not be influenced by
upstream RAF and/or MEK inhibition). To test this, A375 cells
were transfected individually with vectors encoding ABL1,
BLK, FES, MAP3K2, MAP3K8, MOS, NTRK2, SRC, YES1, and
MEK1DD and were treated with the BRAFV600E inhibitor vemura-
fenib, MEK inhibitor CI1040, or the combination of both inhibitors
for 3 h. As expected, cells overexpressing MEK1DD were not
sensitive to vemurafenib, whereas treatment with CI1040 or the
combination treatment completely blocked ERK activation (Fig-
ures 7D and S7F). Similarly, cells that overexpressed MAP3K8,
MAP3K2, or MOS were resistant to vemurafenib but sensitive
to CI1040, suggesting that MEK activity is necessary for the
MAPK-ERK reactivation induced by these three kinases (Fig-
ure 7D, purple boxes). Other POIs, including ABL1, BLK, FES,
NTRK2, SRC, and YES1, showed abundance-dependent ERK
activation, even with the combination treatment of vemurafenib
and CI1040, indicating that these proteins activate ERK in an
MEK-independent manner (Figures 7D and S7F).
Analysis of the POI abundance-dependent p-MEK1/2 levels
confirmed that MAP3K8, MAP3K2, and MOS induced MEK1/2
activity (Figures 7E and S7F). Kinases BLK, FES, SRC, and
YES1 did not cause abundance-dependent MEK1/2 phosphory-
lation in all conditions (Figure 7E), validating that the overex-
pression of these kinases did not activate MEK (Figure S7F).
Abundances of both ABL1 and NTRK2 showed positive correla-
tions with p-MEK1/2 levels only when cells were treated simulta-
neously with CI1040 and vemurafenib (Figure 7E). This suggests
that ABL1 and NTRK2 activate both MEK and ERK. The addition
of CI1040 blocked theMEK-ERK binding (Allen et al., 2003), lead-
ing to the reduced ERK activity and the ERK-MEK negative
feedback, whereas the POI-induced signal inputs on MEK were
constant, resulting in the increased MEK phosphorylation levels
(Figure S7F). The diverse MAPK-ERK reactivation mechanisms
induced by these kinases are illustrated in Figure 7F. We note
(D and E) Overexpression-induced signaling relationships to p-ERK1/2 (D) and p-MEK1/2 (E) under the treatment conditions indicated by line colors.
(F) Illustrations of the diverse MAPK-ERK reactivation mechanisms induced by different assessed POIs and the targets of applied inhibitors, vemurafenib
and CI1040.
(G) Dot plot shows signed-BP-R2 between p-MEK1/2 to p-ERK1/2 for all assessed kinases in HEK293T cells.
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that the data in our kinome and phosphatome screen with
HEK293T cells were indicative of MEK dependency in MAPK-
ERK reactivation, as the kinases MAP3K8, MOS, and MAP3K2
had high signaling relationship strength to p-MEK1/2 (Figure 7G).
Our analysis predicted potential biomarkers of MAPK-ERK reac-
tivation and identified a key mechanism for drug resistance in
melanoma cells carrying the BRAFV600E mutation. We further
classified MAPK-ERK reactivation mechanisms and revealed ki-
nases that induce resistance to BRAF-MEK combined inhibition.
DISCUSSION
The data described here are unique for the broad coverage of the
human kinome and phosphatome, the multiplexed measure-
ment of cellular phosphorylation states and dynamics at sin-
gle-cell resolution, and the wide continuous abundance range
(over three orders of magnitude) over which proteins of interest
were studied. Our analyses enabled protein abundance-deter-
mined functional classification, signaling kinetics quantification,
and the identification of potential biomarkers of drug resistance.
Protein abundance and mRNA expression levels of kinases
and phosphatases have been quantified in normal and diseased
tissues by multiple approaches (Petryszak et al., 2016; Uhlen
et al., 2017; Wang et al., 2015). Our analysis, for the first time,
characterized at kinome- and phosphatome-wide scope how
these proteins differentially modulate signaling network behav-
iors when expressed over a concentration gradient. In the over-
expression effect-based functional classification, we assigned
kinases and phosphatases into 10 clusters that partly agreed
with the kinase and phosphatase catalytic specificities, indi-
cating the dissimilar network alterations between signaling pro-
tein overexpression and activation. Functions of these signaling
proteins include non-catalytic roles such as allosteric regulation
and scaffolding (Kung and Jura, 2016). We showed that our
unique analysis is able to capture these non-catalytic effects
(Figure S3B). This finding is also highly relevant in cancer thera-
peutics in that targeting the catalytic function of a kinase may not
affect the deregulated signaling caused by abundance changes.
Future work with a kinome- and phosphatome-scale catalytically
inactive mutant library would allow global characterization of
signaling protein non-catalytic effects.
Phosphatase overexpression can drive tumor progression,
but the underlying signaling mechanisms have been unclear (Ju-
lien et al., 2011). Our data indicate that rather than directly acti-
vating a cancer-driving signaling pathway, the overexpression of
ERK-specific phosphatases modulates signaling dynamics,
resulting in a prolonged proliferative signal in cells. This supports
the suggestion that phosphatases should be considered thera-
peutic targets for cancer treatment (Bollu et al., 2017; Julien
et al., 2011; Low and Zhang, 2016).
The MAPK-ERK pathway reactivation induced by protein
overexpression is one cause of drug resistance to BRAF inhibi-
tors in melanoma (Johannessen et al., 2010). Therapies that
concurrently inhibit BRAF and MEK have been developed to
simultaneously target the active BRAF signal and the MAPK-
ERK reactivation signal. However, drug resistance still occurs
(Carlino et al., 2014; Eroglu and Ribas, 2016). In our kinome
and phosphatome analysis, we discovered a group of tyrosine
kinases, including SRC, FES, YES1, and BLK, that led to hy-
per-ERK activation independent of MEK activity, suggesting a
mechanism underlying drug resistance to the combined BRAF
and MEK inhibition in melanoma patients with BRAF mutations.
The identified kinases could be used as biomarkers to predict the
drug response to BRAF-MEK combined inhibition and to screen
for patients to be treated with alternative therapies. Compared to
previous population-based assays (Johannessen et al., 2010,
2013), our screening method is more sensitive and robust in
identifying drug resistance-related protein overexpression, as it
assesses signaling variances over a large POI range and can
be applied to highly heterogeneous samples.
Our analysis has several limitations. First, themeasured effects
of overexpression may be indirect; for example, protein overex-
pression may lead to cellular stress that activates MAPK-p38 or
MAPK-JNK cascades. However, even if indirect, these signaling
responses may be typical of such overexpression in diseased
conditions. Second, our mass-cytometry-based analysis used
antibodies targeting 30 specific phosphorylation sites. This
antibody panel does, however, cover the most critical and
informative phosphorylation sites known to be involved in the
cancer-related signaling network. Third, GFP-tag can disrupt
the localization of a kinase or phosphatase. In a previous study,
we cross-validated our results with multiple protein tagging sys-
tems and showed that perturbations on overexpression effects
due to the tag were rare (Lun et al., 2017). Fourth, the catalytic
functionality of many phosphatases requires the co-presence
of a phosphatase catalytic subunit and a phosphatase regulatory
subunit (Chen et al., 2017). Individually overexpressing one of
these subunits may not result in phosphatase activation; rather,
it may affect the kinetics of related dephosphorylating reaction
in cells, and this is what we characterized in the present study.
In summary, we demonstrated, in a human kinome- and phos-
phatome-scale analysis, how the overexpression of individual
signaling proteins modulates signaling networks in an abun-
dance-dependent manner and how the provided datasets can
reveal biological insights underlying diseased conditions. Our
data established that protein expression levels can result in
different signaling states in a population of cells treated identi-
cally. Our analysis expands the functional classification of the
human kinases and phosphatases and suggests 208 signaling
relationships that can be interrogated to improve our under-
standing of signaling causality and network structure. Our data
are also suitable for the inference of signaling pathway kinetics
using mathematical models and for the development of network
reconstruction methods.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
HEK293T cells, obtained from ATCC, were cultured in DMEM (D5671, SIGMA), supplemented with 10% FBS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. A375 cells, a gift from Dr. Lukas Sommer at University of Z€urich, were cultured
in RPMI Medium 1640 (21875-034, GIBCO) with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. For cell passaging or
harvesting, HEK293T cells and A375 cells were incubated with 1X TrypLE Express (Life Technologies) at 37C for 2 min and
5 min, respectively.
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Deposited Data
Integrated raw data and preprocessed data This paper https://doi.org/10.17632/3kh7ypz232.1
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206336147-FCS-file-concatenation-tool
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Single cell debarcoder Zunder et al., 2015 https://github.com/nolanlab/single-cell-
debarcoder
BP-R2 analysis Lun et al., 2017 https://github.com/BodenmillerGroup/Adnet
t-SNE van der Maaten and Hinton, 2008 https://github.com/jkrijthe/Rtsne
STRING Szklarczyk et al., 2017 https://string-db.org/
OmniPath T€urei et al., 2016 http://omnipathdb.org/
Shape-based clustering Genolini et al., 2015 R package ‘kml’
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METHOD DETAILS
Cloning
The human kinase library plasmid kit, containing open reading frames (ORFs) in Gateway Entry vectors, was provided by William
Hahn and David Root (Johannessen et al., 2010; Yang et al., 2011) via Addgene (Kit # 1000000014). The human phosphatase library
was obtained from Dharmacon (OHS4941, ORFeome Human Entry Collection Phosphatase). Destination vectors, including pDEST
pcDNA5 FRT TO-eGFP and pDEST 30 Triple Flag pcDNA5 FRT TO, were kindly provided by Dr. Anne-Claude Gingras at Mount Sinai
Hospital, Toronto, Canada (Couzens et al., 2013). Expression vectors encoding the FLAG- or GFP-tagged fusion proteins were
generated via Gateway Cloning and sequenced before transfection. Vectors for kinase-dead mutants, including pFLAG-CMV-
hErk1 (K71R) (Addgene plasmid # 49329), pCIG AKT3 (K177M) (Addgene plasmid # 73051), pMCL-HA-MAPKK1-8E (K97M) (Addg-
ene plasmid # 40811), IRES-GFP-AXL-KD (K567R) (Addgene plasmid # 65498), and FLAG.PKCepsilon.K/W (K437W) (Addgene
plasmid # 10796) were gifts from Melanie Cobb, Joseph Gleeson, Natalie Ahn, Aaron Meyer, and Alex Toker, respectively (Baek
et al., 2015; Cenni et al., 2002; Meyer et al., 2015; O’Neil et al., 1990).
HEK293T cell transfection and stimulation
HEK293T cells were seeded at the density of 0.7 million per well in 6-well plates. After 24 h, cells were transfected with 2 mg plasmid
and 4 mL of jetPRIME (PolyPlus) per well with the standard protocol provided by the manufacturer. For kinase and phosphatase dou-
ble transfection experiments, cells were transfected with plasmids encoding GFP-tagged kinases and FLAG-tagged phosphatases
16 h and 24 h after seeding, respectively. Half the amounts of plasmid and jetPRIME were used in each round for co-overexpression
experiments. At 18 h after transfection, EGF (Peprotech) was added to a final concentration of 100 ng/ml. At 20 min before a given
EGF stimulation time point, 5-iodo-deoxycytidine (IdU) was added to themedium at the final concentration of 10 mM.At 2min before a
given EGF stimulation time point, mediumwas replaced by 1X TrypLE to induce cell detachment. At the time point, paraformaldehyde
(PFA, from Electron Microscopy Sciences) was added to the cell suspension to a final percentage of 1.6%, and cells were incubated
at room temperature for 10min. If EGF stimulation was not necessary in the experiment, cells were directly harvested and crosslinked
with PFA.
A375 cell transfection
A375 cells were seeded at the density of 0.15 million per well in 6-well plates. At 24 h after seeding, transfection was performed using
2 mg plasmid and 4 mL of X-treme GENE HP reagent (06 366 236 001, Roche) per well with the standard protocol provided by the
manufacturer.
Kinase inhibition with small molecules
BRAFV600E inhibitor vemurafenib andMEK inhibitor CI1040 (stock solutions of 10 mM/mL in DMSO, Selleckchem) were added to the
cells 18 h after transfection independently or in combination at final concentrations of 1 mM and 10 mM, respectively. The same vol-
ume of DMSOwas added to the control samples. Cells were treated either for 3 h or for 2 days. At the end of the treatment, cells were
labeled with IdU during 20-minute incubation and subsequently harvested by 5-minute TrypLE digestion and 10-minute PFA cross-
linking as described above.
Methanol permeabilization
Crosslinked cells were washed twice with cell stainingmedia (CSM, PBSwith 0.5%BSA). After centrifugation, ice-coldmethanol was
used to resuspend the cells, followed by 10-minute permeabilization on ice or for long-term storage at 80C.
Antibody conjugation
TheMaxPAR antibody conjugation kit (Fluidigm) was used to generate isotope-labeled antibodies using themanufacturer’s standard
protocol. After conjugation, the antibody yield was determined based on absorbance of 280 nm. Candor PBS Antibody Stabilization
solution (Candor Bioscience GmbH) was used to dilute antibodies for long-term storage at 4C.
Barcoding and staining protocol
Formalin-crosslinked and methanol-permeabilized cells were washed three times with CSM and once with PBS. Cells were incu-
bated in PBS containing barcoding reagents of 89Y (100 nM), 103Rh (2 mM), 105Pd (100 nM), 106Pd (100 nM), 108Pd (100 nM), 110Pd
(100 nM), 113In (200 nM), 115In (100 nM), and 209Bi (20 nM) for 30 min at room temperature and then washed three times with
CSM. Barcoded cells were then pooled and stained with the metal-conjugated antibody mix (Table S2) at room temperature for
1 h. The antibody mix was removed by washing cells three times with CSM and once with PBS. For DNA staining, iridium-containing
intercalator (Fluidigm) diluted in PBS with 1.6% PFA was incubated with the cells at 4C overnight. On the day of the measurement,
the intercalator solution was removed, and cells were washed with CSM, PBS, and ddH2O. After the last washing step, cells were
resuspended in ddH2O and filtered through a 70-mm strainer.
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Mass cytometry analysis
EQ Four Element Calibration Beads (Fluidigm) were added to cell suspensions in a 1:10 ratio (v/v). Samples were analyzed on a
CyTOF2 (Fluidigm). The manufacturer’s standard operation procedures were used for acquisition at a cell rate of 500 cells per
second. After the acquisition, all FCS files from the same barcoded sample were concatenated (Bodenmiller et al., 2012). Data
were then normalized, and bead events were removed (Finck et al., 2013) before doublet removal and de-barcoding of cells into their
corresponding wells using a doublet-filtering scheme and single-cell deconvolution algorithm (Zunder et al., 2015). Subsequently,
data were processed using Cytobank (https://www.cytobank.org). Additional gating on the DNA channels (191Ir and 193Ir) and
139La/141Pr was used to remove remained doublets, debris and contaminating particulate.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data preprocessing and BP-R2 analysis
Data preprocessing
Raw data were transformed using the inverse hyperbolic sine transform with a cofactor of 5:
data= arcsinhðdataraw=5Þ
Except where use of raw data values is specifically noted, all visualizations and analyses were performed using transformed data.
Data binning
For data binning, the range between the lower and upper 2.5% of observations was divided into ten equal bins bin1,...,bin10. The
observations in the lower and upper 2.5%were assigned to the lowest and highest bins, respectively. In order to be able to compare
expression levels between sampleswithin a time course experiment, all observations of the time coursewere pooled to determine the
binning.
BP-R2
BP-R2 analysis is described in Lun et al., 2017 (https://github.com/BodenmillerGroup/Adnet). In brief, the median of a measured
marker ð~yiÞ was calculated for each bin i. Additionally, the overall mean of the medians of all the 10 bins (m~y ) was calculated (bins
with less than 25 cells were discarded). Then, for each bin, we computed the sum of squared deviations from the bin medians
and the sum of squared deviations from the overall mean of medians. These values were summed over all bins and the BP-R2
was defined as one minus the ratio between them:
R2BP = 1
Pnbins
i =1
1
ni
Pni
j = 1

yij  ~yi
2
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ni
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2
Threshold determination
Following the method described in Lun et al., 2017, we chose the maximum BP-R2 among all the 108 control samples (FLAG-GFP
overexpression and untransfected cells) as a cutoff. Relationships that had a BP-R2 higher than this threshold were considered as
sufficiently strong to be of interest.
Signed-BP-R2
The relationship strengths calculated as BP-R2 were mostly positive, with a few exceptions of negative BP-R2 values mostly from the
cell cycle marker IdU, due to bimodality. These rare and weak negative BP-R2 values were considered as negligible and were there-
fore assigned to 0. This allowed the integration of signaling relationship directionalities, determined by Spearman correlation of bin
medians (rbin), with the relationship strengths (R
2
BP). The signed-BP-R
2 score ðR2signedBPÞ was calculated as:
R2SignedBP =

R2BP; rbinR0
R2BP; rbin < 0
Hierarchical clustering
Hierarchical clustering was performed for kinases and phosphatases on their abundance-dependent signaling relationships, as
signed-BP-R2, to all measured phosphorylation sites with and without 10-minute EGF stimulation. Ward’s method and Euclidean
distances (Ward, 1963) were used for the clustering, and the hierarchical tree was cut at the height of 5 to obtain 10 clusters of kinases
and phosphatases as shown in Figure S2A.
t-SNE analysis
t-SNE analysis was performed with the Package ‘Rtsne’ in R.
Functional enrichment and association analysis using STRING database
The functional enrichment and interaction enrichment analyses were performed using the STRING database v10.5 (Szklarczyk et al.,
2017). All the kinases and phosphates tested were mapped to STRING protein name-space establishing the background protein set
for the further analysis. The functional enrichment p values were corrected using Benjamini and Hochberg method (Benjamini and
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Hochberg, 1995) (the detailed description of the statistical methods can be found in Franceschini et al., 2013). To test whether the
functional signal within the clusters arises exclusively from a homology between the proteins, the homologous proteins were grouped
together into one node, and, therefore, the proteins that exhibited high or medium homology did not contribute independently to the
enrichment functional term count. In order to form the grouped representation of the STRING network the single-linkage clustering
methodwas applied to the homology relationships between the proteins in which neighbors were defined as having a self-normalized
bit score (BLAST bit score of alignment between the two proteins divided by the bit score of self-alignment of shorter of the two
proteins) equal to or higher than 0.2. For each functional term the grouped node contributed to the enrichment count when one or
more of the proteins forming the group were annotated with the term in question. This process was applied to both the clusters
and the background separately to ensure that for the groups in which proteins were shared between the cluster and the background
the functional term was counted in both sets.
Shortest signed directed path analysis using OmniPath
The pathway analysis was performed for all signaling relationships between overexpressed POIs and measured phosphorylation
sites using OmniPath (http://omnipathdb.org/), a collection of literature curated human signaling pathways integrated from 25 data-
bases (pathway databases: TRIP, SPIKE, SignaLink3, Guide2Pharma, CA1, ARN, NRF2ome,Macrophage, DeathDomain, PDZBase,
Signor; interaction databases: BioGRID, CancerCellMap, MPPI, DIP, InnateDB, MatrixDB; PTM databases: PhosphoSite, DEPOD,
LMPID, phosphoELM, ELM, DOMINO, dbPTM, HPRD-phos) (T€urei et al., 2016). The shortest path was determined based on based
on Breadth-First Search methods, computed through a Python module called pyPath (T€urei et al., 2016).
Shape-based clustering
For each signaling relationship between a phosphorylation site and an overexpressed protein, the median phosphorylation abun-
dance in each pre-defined bin was calculated using arcsinh transformed data. K-means shape-based clustering was performed
with the package ‘kml’ (Genolini et al., 2015) in R for all strong POI abundance-dependent signaling relationships after 0-1 normal-
ization on phosphorylation abundance (in Figure 1D), or for signaling trajectories over 1-hour EGF stimulation time course without
data normalization (in Figure S6). Euclidean distance was used as similarity measure.
Selection of strong signaling dynamic influencing POIs
For each pair of signaling relationships between an overexpressed POI and a measured phosphorylation site, the delta BP-R2 score
was calculated as the signed-BP-R2 value with 10-minute EGF stimulation minus the signed-BP-R2 value in unstimulated cells. We
selected the 10 POIs with the largest positive differences in signed-BP-R2, the 10 POIs with the largest negative difference in signed-
BP-R2, the 20 POIs with the most signaling relationships in the 99th percentile of the difference in signed-BP-R2, and the 10 central
signaling dynamic regulators in theMAPK/ERK and AKT pathways known from the literature (Steelman et al., 2011). Some POIs were
in more than one set, so this resulted in 39 kinases and phosphatases.
Signaling amplitudes analysis
The signaling amplitudes analysis was adapted from our previous methods (Lun et al., 2017). The fold change of median phosphor-
ylation abundance for each bin in EGF-stimulated samples over the corresponding bin of the unstimulated sample (EGF 0 min) was
calculated using the raw count. The amplitude for each bin was identified as the maximal fold change over all time points. Amplitude
ratios between the second highest and the second lowest bin amplitudes were computed for all samples, and the highest amplitude
ratio in all FLAG-GFP overexpression and untransfected controls was used to determine the cutoff for robust and strong abundance-
dependent changes.
DATA AND SOFTWARE AVAILABILITY
All raw data and pre-analyzed data are available at Mendeley Data under the following link:
https://doi.org/10.17632/3kh7ypz232.1.
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